Graham Capital Management’s Editas Medicine EDIT Stock Holding History

Graham Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-139,904	Closed	-$287K	–	1255
2025 Q4	$287K	Buy	139,904 +72,820	+109%	+$210K	0.01%	878
2025 Q3	$233K	Buy	67,084 +26,451	+65%	+$73.8K	﹤0.01%	980
2025 Q2	$89.4K	Buy	+40,633	New	+$66.5K	﹤0.01%	1215
2024 Q2	–	Sell	-62,106	Closed	-$461K	–	1118
2024 Q1	$461K	Buy	62,106 +46,725	+304%	+$388K	0.01%	651
2023 Q4	$156K	Sell	15,381 -16,975	-52%	-$149K	﹤0.01%	872
2023 Q3	$252K	Sell	32,356 -732	-2%	-$6.28K	0.01%	779
2023 Q2	$272K	Buy	+33,088	New	+$288K	0.01%	724
2022 Q4	–	Sell	-158,186	Closed	-$1.94M	–	1104
2022 Q3	$1.94M	Buy	158,186 +14,106	+10%	+$220K	0.08%	234
2022 Q2	$1.7M	Buy	+144,080	New	+$1.93M	0.07%	260
2022 Q1	–	Sell	-12,429	Closed	-$329K	–	920
2021 Q4	$329K	Buy	+12,429	New	+$428K	0.01%	287

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Graham Capital Management's EDIT Position: Q1 2026 in Review

Graham Capital Management sold out of Editas Medicine (EDIT) in Q1 2026, closing a stake of 139,904 shares — an estimated $287K sold.

Graham Capital Management first reported a position in EDIT in Q4 2021 and held it in 10 quarters. The position peaked at $1.94M in Q3 2022. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Graham Capital Management reported no remaining Editas Medicine position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 139,904 Editas Medicine shares in Q1 2026, an estimated $287K.
Graham Capital Management first reported a position in Editas Medicine in Q4 2021 and held it in 10 quarters.
Graham Capital Management's Editas Medicine position peaked at $1.94M in Q3 2022.
207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.